UPDATE 1-Novartis in advanced talks to buy Cytokinetics- WSJ

-0.62%

-0.23% Post

-0.24%

+0.23%

0.00% Post

Dow Jones Industrial Average DJI	48114.26	-0.62%
Cytokinetics, Incorporated CYTK	62.02 62.27	-0.23% +0.40% Post
S&P 500 index SPX	6800.26	-0.24%
NASDAQ IXIC	23111.46	+0.23%
Novan, Inc. NOVN		0.00% 0.00% Post

Adds details in paragraph 2, shares in paragraph 3

Jan 8 (Reuters) - Swiss drugmaker Novartis NOVN.S is close to acquiring Cytokinetics CYTK.O and the deal could be finalized as soon as this week, the Wall Street Journal reported on Monday, citing people familiar with the matter.

The deal, if finalized, could help Novartis gain access to Cytokinetics' experimental treatment for an inherited chronic heart disease that can cause cardiac arrest.

Shares of Cytokinetics rose over 16% after the report.

San Francisco-based Cytokinetics is developing a drug called aficamten for hypertrophic cardiomyopathy (HCM), which causes thickening of the heart muscles leading to a likely cardiac arrest.

(Reporting by Shubhendu Deshmukh in Bengaluru; Editing by Shailesh Kuber)

((ShubhenduSatish.Deshmukh@thomsonreuters.com;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.